Archive for November 2019
Tadalafil in Pharmacy Compounding
Originally designed to treat cardiovascular diseases, phosphodiesterase-5 (PDE5) inhibitors made a major splash on the pharmaceutical market in 1998 with the approval of Viagra®. By far, it was the blockbuster drug of the decade. Other PDE5 inhibitors were soon to follow, and patent-expiration dates have been an interesting phenomenon to watch, with multiple extensions involved.…
Read More